Start: September 14, 2018
End: December 31, 2019
Enrollment: 60
This Phase 1 study is testing the investigational drug AL001 as a possible treatment for frontotemporal dementia (FTD) in healthy volunteers and people with FTD who also have a granulin mutation (PGRN).
Minimum Age: 18 Years
Maximum Age: 80 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Alector Inc.
Source: ClinicalTrials.gov ID: NCT03636204